Related Experiment Video
Updated: May 12, 2026
A Mouse Model to Assess Innate Immune Response to Staphylococcus aureus Infection
Published on: February 28, 2019
Evaluating Topical Nitric Oxide Formulations Against an Atopic Dermatitis Methicillin-Resistant S. Aureus Isolate in
Background:
Atopic dermatitis (AD) is a skin disorder characterized by reduced skin barrier function, which often leads to recurring infections, predominantly by Staphylococcus aureus and methicillin-resistant S. aureus, that exacerbate disease severity. Managing these infections is made challenging by antibiotic resistance and biofilm formation. Nitric oxide (NO) has emerged as a promising antimicrobial treatment that can disperse biofilm and may provide an alternative treatment for AD infections.
Methods:
This study evaluated the antimicrobial efficacy of 3 topical NO-releasing formulations at various concentrations against established MRSA infections, from an AD-derived isolate, in a porcine wound infection model. Partial thickness wounds were inoculated and, after 48 hours of biofilm formation, were treated daily with NO formulations or vehicle control, or left untreated. Wounds were recovered for baseline, day 4, or day 7 bacterial enumeration.
Results:
All tested NO-releasing formulations substantially reduced MRSA burden compared with baseline counts, and most effectively with the highest concentrations. 20% NO+GEL resulted in a significant reduction of 99.23% compared with baseline at day 7. The 16% NO+UNG treatment, compared with the untreated control, had bacterial reductions on day 4 and day 7 of greater than 99.5%. The greatest reduction of 99.97% (>3 Log CFU/mL) was observed for 6% NO+CREAM compared with the untreated control group at day 7.
Conclusions:
NO-releasing treatments have considerable efficacy against MRSA infections and biofilm. These findings support the potential of NO as an antimicrobial treatment for AD patients, and further evaluation should be conducted to assess clinical efficacy.
Insights
Nitric oxide (NO) formulations show significant efficacy in reducing methicillin-resistant Staphylococcus aureus (MRSA) infections and biofilms in a porcine wound model. These findings suggest NO as a potential alternative treatment for atopic dermatitis (AD) infections.
Area of Science:
- Dermatology
- Infectious Diseases
- Biomedical Engineering
Background:
- Atopic dermatitis (AD) is linked to impaired skin barrier function, increasing susceptibility to infections like Staphylococcus aureus and methicillin-resistant S. aureus (MRSA).
- Antibiotic resistance and biofilm formation complicate the management of these infections in AD patients.
- Nitric oxide (NO) demonstrates antimicrobial properties and biofilm dispersal capabilities, offering a potential therapeutic alternative.
Purpose of the Study:
- To evaluate the antimicrobial efficacy of topical nitric oxide (NO)-releasing formulations against MRSA infections in a preclinical model.
- To assess the impact of NO formulations on MRSA biofilm reduction in a porcine wound infection model.
Main Methods:
- Three topical NO-releasing formulations at varying concentrations were tested against MRSA isolates from AD patients.
- A porcine partial-thickness wound infection model was used, with wounds inoculated and allowed to form biofilms before treatment.
- Treatments included daily application of NO formulations or vehicle control, with bacterial enumeration at baseline, day 4, and day 7.
Main Results:
- All tested NO formulations significantly reduced MRSA bacterial burden compared to baseline.
- Higher concentrations of NO formulations generally yielded greater reductions in MRSA.
- Specific formulations demonstrated substantial reductions: 20% NO+GEL (99.23%), 16% NO+UNG (>99.5%), and 6% NO+CREAM (99.97%) compared to controls at day 7.
Conclusions:
- Topical NO-releasing treatments exhibit significant antimicrobial efficacy against MRSA infections and biofilms.
- These results support the potential of NO as an alternative antimicrobial strategy for atopic dermatitis.
- Further clinical studies are warranted to confirm the efficacy and safety of NO treatments in AD patients.
More Related Videos
08:30A Novel High-Throughput Ex Vivo Ovine Skin Wound Model for Testing Emerging Antibiotics
Published on: September 16, 2022
07:32Evaluating the Immune Response of a Nanoemulsion Adjuvant Vaccine Against Methicillin-Resistant Staphylococcus aureus MRSA Infection
Published on: September 1, 2023
